The Optic Neuritis drugs in development market research report provides comprehensive information on the therapeutics under development for Optic Neuritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Optic Neuritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Optic Neuritis by 13 companies/universities/institutes. The top development phase for Optic Neuritis is preclinical with five drugs in that stage. The Optic Neuritis pipeline has ten drugs in development by companies and two by universities/ institutes. Some of the companies in the Optic Neuritis pipeline products market are: Parvus Therapeutics, University of Pennsylvania and Noveome Biotherapeutics.
The key targets in the Optic Neuritis pipeline products market include Deoxycytidine Kinase, IgG Receptor FcRn Large Subunit p51, and Neuropilin 1.
The key mechanisms of action in the Optic Neuritis pipeline product include Ribonucleoside Diphosphate Reductase Inhibitor with one drug in Preclinical. The Optic Neuritis pipeline products include nine routes of administration with the top ROA being Intravenous and seven key molecule types in the Optic Neuritis pipeline products market including Small Molecule, and Peptide.
Optic Neuritis overview
Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon, and flashing lights. Risk factors include age and genetic mutations.
For a complete picture of Optic Neuritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
